Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
Boehringer Ingelheim and Palatin Technologies enter into a global research collaboration and licensing agreement
(Image Credit: AdobeStock/Vittaya_25) Boehringer Ingelheim and Palatin Technologies have entered into a global research collaboration and licensing agreement to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases. Under the terms of the agreement, Palatin will receive…
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye – Nature
Infographic: landmark trials in neuro-ophthalmology—results of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) | Eye Nature Source: Author: | Date: 2025-07-04 07:00:00 Source: Author: | Date: 2025-07-04 07:00:00
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology – Stanford Medicine
New research uncovers promising treatment for neurodegenerative diseases like ALS, glaucoma | Ophthalmology Stanford Medicine Source: Author: | Date: 2025-02-20 08:00:00 Source: Author: | Date: 2025-02-20 08:00:00
Lenz Therapeutics Reports Study Success for Presbyopia
Lenz Therapeutics announced positive topline results from its Phase 3 CLARITY study, evaluating two investigational formulations, LNZ100 and LNZ101, aimed at treating presbyopia. The study’s findings showcase the effectiveness and safety of these formulations, particularly highlighting LNZ100 (1.75% aceclidine) for…
Zeiss Completes Acquisition of DORC
In a significant move for the ophthalmology sector, Carl Zeiss Meditec announced the successful acquisition of 100% shares of the Dutch Ophthalmic Research Center (DORC), a transaction that has now received all necessary regulatory approvals. This acquisition from Eurazeo SE,…
Qlaris Bio Begins Phase 2 Trials of QLS-111 for Eye Conditions
Qlaris Bio has commenced two critical Phase 2 trials in the United States for its innovative intraocular pressure (IOP)-lowering product, QLS‑111. These masked, randomized clinical trials are designed to investigate the efficacy of QLS‑111 in patients suffering from ocular hypertension…
West Point and Verséa Sign Supply Deal for Ocular Products
In a significant move for ocular health and treatment, West Point Optical Group (WPOG), the operator of 86 Pearle Vision stores, has joined forces with Verséa Ophthalmics in an exclusive partnership supply agreement. Under this new deal, Verséa Ophthalmics is…
Pantheon Vision Gets Another $1.8M for Corneal Implants
Pantheon Vision, a pioneering medical device company in the pre-clinical stage focused on developing bioengineered corneal implants, has secured an additional $1.8 million in funding. This recent financial boost is part of a second tranche from KeraLink International (KLI), following…
ViaLase Raises $40M for Glaucoma Laser Tech
ViaLase has successfully completed a Series C financing round, raising a substantial $40 million. This funding boost is set to accelerate the development, regulatory approval, and commercialization efforts of the ViaLase Laser, a pioneering medical device developed for the treatment…